Cost-effectiveness analysis of routine childhood immunization with 20-valent versus 15-valent pneumococcal conjugate vaccine in the Netherlands

Abstract Background The Netherlands currently uses the 15-valent pneumococcal conjugate vaccine (PCV15) in a 2 + 1 schedule in its pediatric national immunization program. The European Medicines Agency recently approved the use of 20-valent PCV (PCV20) in a 3 + 1 schedule for the prevention of pneumococcal disease in children. This study evaluates the cost-effectiveness of routine childhood immunization with PCV20 (3 + 1) versus PCV15 (2 + 1) in the Netherlands. Methods A decision-analytic Markov model was used to track the health (pneumococcal disease, sequelae, and death) and economic (treatment costs and indirect costs, including productivity losses) outcomes of a single birth cohort of 165,977 infants over their lifetimes starting in 2025. Disease incidence, vaccination rates, and vaccine effectiveness were derived from published sources, and indirect effects, such as herd protection, were included. The model adopted a societal perspective, with costs adjusted to 2025 euros and discounted at 3.0%. Scenario and sensitivity analyses were used to assess the effects of variation in input parameters. Results In the base case, compared to PCV15, PCV20 prevented 139 more cases of invasive pneumococcal disease, 638 more pneumonia cases, 3,393 more cases of acute otitis media, and 3 more episodes of post-meningeal sequelae over a lifetime horizon at an additional cost of €13,201,279. With 24 quality-adjusted life-years (QALYs) gained by vaccination with PCV20 vs. PCV15, the incremental cost-effectiveness ratio was €530,629/QALY, well above the Dutch willingness-to-pay threshold of €20,000–80,000/QALY. Conclusion Routine childhood immunization with PCV20 instead of PCV15 is not cost-effective in the Netherlands.

Authors

Institutions

Publication Details

Journal
Cost Effectiveness and Resource Allocation
Published
2026-11-17
DOI
https://doi.org/10.1186/s12962-026-00857-3
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cost-effectiveness analysis of routine childhood immunization with 20-valent versus 15-valent pneumococcal conjugate vaccine in the Netherlands

Jessica Papadopoulos Weaver, F Christiaan K Dolk, Eleana Tsoumani, Min Huang
8 links
Cost Effectiveness and Resource Allocation
Pneumonia and Respiratory Infections
article

Cost-effectiveness analysis of routine childhood immunization with 20-valent versus 15-valent pneumococcal conjugate vaccine in the Netherlands

Jessica Papadopoulos Weaver, F Christiaan K Dolk, Eleana Tsoumani, Min Huang
article en

Abstract

Abstract Background The Netherlands currently uses the 15-valent pneumococcal conjugate vaccine (PCV15) in a 2 + 1 schedule in its pediatric national immunization program. The European Medicines Agency recently approved the use of 20-valent PCV (PCV20) in a 3 + 1 schedule for the prevention of pneumococcal disease in children. This study evaluates the cost-effectiveness of routine childhood immunization with PCV20 (3 + 1) versus PCV15 (2 + 1) in the Netherlands. Methods A decision-analytic Markov model was used to track the health (pneumococcal disease, sequelae, and death) and economic (treatment costs and indirect costs, including productivity losses) outcomes of a single birth cohort of 165,977 infants over their lifetimes starting in 2025. Disease incidence, vaccination rates, and vaccine effectiveness were derived from published sources, and indirect effects, such as herd protection, were included. The model adopted a societal perspective, with costs adjusted to 2025 euros and discounted at 3.0%. Scenario and sensitivity analyses were used to assess the effects of variation in input parameters. Results In the base case, compared to PCV15, PCV20 prevented 139 more cases of invasive pneumococcal disease, 638 more pneumonia cases, 3,393 more cases of acute otitis media, and 3 more episodes of post-meningeal sequelae over a lifetime horizon at an additional cost of €13,201,279. With 24 quality-adjusted life-years (QALYs) gained by vaccination with PCV20 vs. PCV15, the incremental cost-effectiveness ratio was €530,629/QALY, well above the Dutch willingness-to-pay threshold of €20,000–80,000/QALY. Conclusion Routine childhood immunization with PCV20 instead of PCV15 is not cost-effective in the Netherlands.

Cost Effectiveness and Resource Allocation
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), MSD (Netherlands) (NL), MSD (Greece) (GR)
Merck
Good health and well-being
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon